Learn how a man's dream of becoming a professional python hunter resulted in the capture of the second-largest python in Florida history.

Netflix’s latest Korean blockbuster The Great Flood has surged to the top of the platform’s global charts for nonglobal films, but audiences are divided over its cryptic ending and philosophical twist ...

Joachim Trier goes deep into the silent ending of his Oscar contender, breaking down how he constructed a script that built toward such a powerful moment. “I’m out on a limb with this one,” said Trier ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Netflix's new show The Abandons has a true cliffhanger ending, and we're here to break it down. One of the love stories of the season does get a (kind of) resolution. Did [SPOILER] and [SPOILER] ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...